Autocrine growth inhibition by transforming growth factor β-1 (TGFβ-1) in human neuroendocrine tumour cells

Gut

Volumn 52, Issue 9, 2003, Pages 1308-1316

  Wimmel, A ^a   Wiedenmann, B ^a   Rosewicz, S ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL COUNT; CELL CYCLE; CELL CYCLE G1 PHASE; CELL LINE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE TUMOR; ONCOGENE C MYC; PARACRINE SIGNALING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

AUTOCRINE COMMUNICATION; BLOTTING, WESTERN; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOPLASM PROTEINS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMAD PROTEINS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED;

EID: 0042508786     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.9.1308     Document Type: Article

References (37)

1. Rindi G, Villanacci V, Ubiali A. Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors. Digestion 2000;62(suppl 1):19-26.
2. Schmitt-Gräff A, Nitschke R, Wiedenmann B. (Gastroenteropancreatic neuroendocrine/endocrine tumors. Current pathologic-diagnostic view). Pathologe 2001;22:105-13.
3. Bast RC, Kufe DW, Pollock RE, et al. Neoplasms of the Endocrine Glands. Cancer Medicine, 5th edn. Canada: BC Decker Inc, 2000.
4. Calender A. Molecular genetics of neuroendocrine tumors. Digestion 2000;62(suppl 1):3-18.
5. Chaudhry A, Funa K, Öberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 1993;32:107-14.
6. Miyazono K. TGF-beta/SMAD signaling and its involvement in tumor progression. Biol Pharm Bull 2000;23:1125-30.
7. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000;1:169-78.
8. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
9. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-71.
10. Akhurst RJ, Derynck R. TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol 2001;11:S44-51.
11. Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol 2001;186:153-68.
12. Detjen KM, Welzel M, Farwig K, et al. Molecular mechanism of interferon alfa- mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 2000;118:735-48.
13. Carcamo J, Weis FM, Ventura F, et al. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin. Mol Cell Biol 1994;14:3810-21.
14. Le Roy C, Maisnier-Patin K, Leduque P, et al. Overexpression of a dominant-negative type II TGFbeta receptor tagged with green fluorescent protein inhibits the effects of TGFbeta on cell growth and gene expression of mouse adrenal tumor cell line Y-1 and enhances cell tumorigenicity. Mol Cell Endocrinol 1999;158:87-98.
15. Giehl K, Seidel B, Gierschik P, et al. TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. Oncogene 2000;19:4531-41.
16. Bartsch D, Hahn SA, Danichevski KD, et al. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene 1999;18:2367-71.
17. Grau AM, Zhang L, Wang W, et al. Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 1997;57:3929-34.
18. Shin SI, Freedman VH, Risser R, et al. Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci U S A 1975;72:4435-9.
19. Venkatasubbarao K, Ahmed MM, Mohiuddin M, et al. Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma. Anticancer Res 2000;20:43-51.
20. Chaudhry A, Öberg K, Gobl A, et al. Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res 1994;14:2085-91.
21. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
22. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002;12:22-9.
23. Staller P, Peukert K, Kiermaier A, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001;3:392-9.
24. Voss M, Wolff B, Savitskaia N, et al. TGFbeta-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expression. Int J Oncol 1999;14:93-101.
25. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
26. Simeone DM, Pham T, Logsdon CD. Disruption of TGFbeta signaling pathways in human pancreatic cancer cells. Ann Surg 2000;232:73-80.
27. Bartsch D, Barth P, Bastian D, et al. Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas. Cancer Lett 1999;139:43-9.
28. Villanueva A, Garcia C, Paules AB, et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 1998;17:1969-78.
29. Schroy P, Rifkin J, Coffey RJ, et al. Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide. Cancer Res 1990;50:261-5.
30. Hsu S, Huang F, Hafez M, et al. Colon carcinoma cells switch their response to transforming growth factor beta 1 with tumor progression. Cell Growth Differ 1994;5:267-75.
31. Perlman R, Schiemann WP, Brooks MW, et al. TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol 2001;3:708-14.
32. Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1999;10:303-60.
33. Chen RH, Chang TY. Involvement of caspase family proteases in transforming growth factor- beta-induced apoptosis. Cell Growth Differ 1997;8:821-7.
34. Saltzman A, Munro R, Searfoss G, et al. Transforming growth factor-beta-mediated apoptosis in the Ramos B- lymphoma cell line is accompanied by caspase activation and Bcl- XL downregulation. Exp Cell Res 1998;242:244-54.
35. Grande JP, Warner GM, Walker HJ, et al. TGF-beta1 is an autocrine mediator of renal tubular epithelial cell growth and collagen IV production. Exp Biol Med (Maywood) 2002;227:171-81.
36. Huang F, Newman E, Theodorescu D, et al. Transforming growth factor beta 1 (TGF beta 1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF beta 1 antisense expression plasmid. Cell Growth Differ 1995;6:1635-42.
37. Deng X, Bellis S, Yah Z, et al. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta 1 in cells with nonfunctional TGF-beta receptor type III. Cell Growth Differ 1999;10:11-8.